Lung Cancer Clinical Trials in Detroit

Showing 161-180 of 342 trials

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

NCT03473925

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

Solid TumorsNon-small Cell Lung CancerCastration Resistant Prostate Cancer+1 more

Merck Sharp & Dohme LLC107 participantsStarted Apr 2018

Scottsdale, Arizona, United States • Sarasota, Florida, United States • Baltimore, Maryland, United States +11 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

NCT01970865

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Pfizer364 participantsStarted Jan 2014

Fayetteville, Arkansas, United States • Rogers, Arkansas, United States • Orange, California, United States +74 more locations

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Lung Cancer Trials in Other Cities

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Lung EpiCheck Biomarkers Development Study

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Other Conditions in Detroit